BLOOD, LYMPH AND RELATED CONDITIONS:@0.084848:0.038601:0.564720:0.038601:0.564720:0.019343:0.084848:0.019343:0.013500:0.010866:0.020438:0.020438:0.017498:0.006515:0.006515:0.008735:0.013923:0.021613:0.013923:0.016063:0.006515:0.017404:0.017404:0.017498:0.006515:0.014276:0.012606:0.010866:0.015466:0.010019:0.012606:0.017498:0.006515:0.019121:0.020438:0.017404:0.017498:0.005315:0.010019:0.005315:0.020438:0.017404:0.011712
82:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
is mandatory. While peripheral blood may :@0.084848:0.096166:0.481090:0.096166:0.481090:0.080410:0.084848:0.080410:0.003848:0.007466:0.005426:0.018049:0.013143:0.011738:0.013181:0.013143:0.006523:0.012604:0.005792:0.010314:0.005330:0.005403:0.018473:0.011738:0.003848:0.003848:0.012508:0.005417:0.013123:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.005417:0.013123:0.003848:0.012604:0.012604:0.013181:0.005413:0.018049:0.013143:0.010314:0.005330
not demonstrate malignant blasts, bone-:@0.084848:0.112358:0.475767:0.112358:0.475767:0.096602:0.084848:0.096602:0.011738:0.012604:0.006523:0.007937:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.007947:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.007947:0.013123:0.003848:0.013143:0.007466:0.006523:0.007466:0.005330:0.007947:0.013123:0.012604:0.011738:0.012508:0.006388
marrow biopsy will  always  show >20% :@0.084848:0.128551:0.481086:0.128551:0.481086:0.112795:0.084848:0.112795:0.018049:0.013143:0.005792:0.005711:0.012604:0.015990:0.014393:0.013123:0.003848:0.012604:0.013123:0.007466:0.010325:0.014393:0.015990:0.003848:0.003848:0.003848:0.005330:0.009077:0.013143:0.003848:0.015990:0.013143:0.010314:0.007466:0.005330:0.009079:0.007466:0.011738:0.012604:0.015990:0.014393:0.011661:0.010660:0.010660:0.014913:0.005330
blasts. Immunophenotyping differentiates :@0.084848:0.144743:0.481101:0.144743:0.481101:0.128987:0.084848:0.128987:0.013123:0.003848:0.013143:0.007466:0.006523:0.007466:0.005330:0.007847:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.013123:0.011738:0.012508:0.011738:0.012604:0.006523:0.010314:0.013123:0.003848:0.011738:0.012950:0.007832:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.012508:0.007466:0.005330
precursor  B (80%) from  precursor  T  (15%) :@0.084848:0.160936:0.481092:0.160936:0.481092:0.145180:0.084848:0.145180:0.013123:0.005715:0.012508:0.012450:0.011699:0.005792:0.007466:0.012604:0.005792:0.005330:0.003673:0.011045:0.009025:0.007100:0.010660:0.010672:0.014913:0.007100:0.009025:0.006042:0.005711:0.012604:0.018049:0.005330:0.003683:0.013123:0.005715:0.012508:0.012450:0.011699:0.005792:0.007466:0.012604:0.005792:0.005330:0.003677:0.008197:0.005330:0.003683:0.007100:0.010660:0.010660:0.014913:0.007100:0.005330
ALL (see Figure 3). Cytogenetic analysis :@0.084848:0.177128:0.481051:0.177128:0.481051:0.161372:0.084848:0.161372:0.014239:0.008890:0.008890:0.010314:0.007100:0.007466:0.012508:0.012508:0.010314:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.010314:0.010660:0.007100:0.005330:0.010314:0.015644:0.010314:0.006523:0.012604:0.012950:0.012508:0.011726:0.012508:0.006523:0.003848:0.012450:0.010314:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.005330
is useful and will show either a favourable :@0.084848:0.193321:0.481076:0.193321:0.481076:0.177565:0.084848:0.177565:0.003848:0.007466:0.006331:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.006331:0.013143:0.011738:0.013181:0.006331:0.015990:0.003848:0.003848:0.003848:0.006331:0.007466:0.011738:0.012604:0.015990:0.006331:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.006319:0.013143:0.006331:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
pattern or an unfavourable arrangement :@0.084848:0.209513:0.481099:0.209513:0.481099:0.193757:0.084848:0.193757:0.013123:0.013143:0.006523:0.006523:0.012508:0.006188:0.011738:0.007004:0.012604:0.005792:0.007004:0.013143:0.011738:0.007004:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.007004:0.013143:0.005792:0.005792:0.013143:0.011738:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330
that also includes the complex karyotypes :@0.084848:0.225706:0.481099:0.225706:0.481099:0.209950:0.084848:0.209950:0.006523:0.011738:0.013143:0.006523:0.005024:0.013143:0.003848:0.007466:0.012604:0.005042:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005042:0.006523:0.011738:0.012508:0.005024:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.005030:0.009660:0.013143:0.005792:0.010314:0.012604:0.006523:0.010314:0.013123:0.012508:0.007466:0.005330
(five or more abnormalities). The Philadel-:@0.084848:0.241898:0.475748:0.241898:0.475748:0.226142:0.084848:0.226142:0.007100:0.004686:0.004686:0.010660:0.012508:0.006616:0.012604:0.005792:0.006606:0.018049:0.012604:0.005709:0.012508:0.006612:0.013143:0.013123:0.011738:0.012604:0.006319:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.007100:0.005330:0.006627:0.008197:0.011738:0.012508:0.006606:0.011392:0.011738:0.003848:0.003848:0.013143:0.013181:0.012508:0.003848:0.006388
phia chromosome (Ph1; BCR-ABL p190Kd) :@0.084848:0.258091:0.481074:0.258091:0.481074:0.242335:0.084848:0.242335:0.013123:0.011738:0.003848:0.013143:0.005850:0.012450:0.011738:0.005713:0.012604:0.018049:0.012604:0.007466:0.012594:0.018049:0.012508:0.005838:0.007100:0.011392:0.011738:0.010660:0.005330:0.005834:0.011045:0.015644:0.011680:0.006388:0.014239:0.011045:0.008890:0.005836:0.013123:0.010660:0.010660:0.010660:0.011372:0.013181:0.007100:0.005330
is uncommon in paediatric ALL, but oc-:@0.084848:0.274138:0.475758:0.274138:0.475758:0.258382:0.084848:0.258382:0.003848:0.007466:0.009563:0.011699:0.011738:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.009563:0.003848:0.011738:0.009563:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.009563:0.014239:0.008890:0.008890:0.005330:0.009563:0.013123:0.011699:0.006523:0.009563:0.012604:0.012450:0.006388
curs in 25-35% of adult ALL.  The PH1 chro-:@0.084848:0.290185:0.475770:0.290211:0.475770:0.274455:0.084848:0.274429:0.012450:0.011699:0.005792:0.007466:0.005080:0.003848:0.011738:0.005080:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.005080:0.012604:0.006042:0.005080:0.013143:0.013181:0.011699:0.003848:0.006523:0.005080:0.014239:0.008890:0.008890:0.005330:0.012429:0.005080:0.008197:0.011738:0.012508:0.005080:0.011392:0.013143:0.010660:0.005080:0.012450:0.011738:0.005709:0.012604:0.585956
11:@0.331569:0.284592:0.343999:0.284592:0.343999:0.275406:0.331569:0.275406:0.006215:0.006215
mosome  may be detected  by reverse :@0.084847:0.306258:0.481085:0.306258:0.481085:0.290502:0.084847:0.290502:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.005330:0.007168:0.018049:0.013143:0.010314:0.012508:0.013123:0.012508:0.012508:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330:0.007168:0.013123:0.010314:0.012508:0.005713:0.012508:0.010660:0.012508:0.005792:0.007466:0.012508:0.005330
transcriptase polymerase chain reaction :@0.084847:0.322305:0.481085:0.322305:0.481085:0.306549:0.084847:0.306549:0.006523:0.005792:0.013143:0.011738:0.007466:0.012450:0.005792:0.003848:0.013123:0.006523:0.013143:0.007466:0.012508:0.010198:0.013123:0.012604:0.003848:0.010314:0.018049:0.012508:0.005792:0.013143:0.007466:0.012508:0.010198:0.012450:0.011738:0.013143:0.003848:0.011738:0.010198:0.005713:0.012508:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
(RT-PCR)  and  by  fluorescence :@0.084847:0.338352:0.379727:0.338352:0.379727:0.322596:0.084847:0.322596:0.007100:0.011794:0.008197:0.006388:0.011392:0.015644:0.011680:0.007100:0.005330:0.003929:0.013143:0.011738:0.013181:0.005330:0.003933:0.013123:0.010314:0.005330:0.003935:0.004666:0.004666:0.011699:0.012604:0.005705:0.012508:0.007466:0.012450:0.012508:0.011738:0.012450:0.012508:0.005330
in  situ:@0.383662:0.338352:0.438051:0.338352:0.438051:0.322596:0.383662:0.322596:0.003848:0.011738:0.005330:0.003935:0.007466:0.003848:0.006523:0.011699
  hy-:@0.438051:0.338352:0.475754:0.338352:0.475754:0.322596:0.438051:0.322596:0.005330:0.003933:0.011738:0.010314:0.006388
bridisation (FISH).:@0.084847:0.354399:0.241230:0.354399:0.241230:0.338643:0.084847:0.338643:0.013123:0.005792:0.003848:0.013181:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007100:0.009333:0.004349:0.009583:0.013143:0.007100:0.005330
PROGNOSTIC FACTORS:@0.084848:0.386822:0.320888:0.386822:0.320888:0.369006:0.084848:0.369006:0.011973:0.012401:0.017960:0.017960:0.015822:0.017960:0.011118:0.008980:0.005987:0.016677:0.005987:0.010263:0.015822:0.016677:0.008980:0.017960:0.012401:0.011118
Certain factors at the time of diagnosis or :@0.084848:0.404016:0.481113:0.404016:0.481113:0.388260:0.084848:0.388260:0.015644:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.006148:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.006146:0.013143:0.006523:0.006158:0.006523:0.011738:0.012508:0.006146:0.006523:0.003848:0.018049:0.012508:0.006158:0.012604:0.006042:0.006158:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.006158:0.012604:0.005792:0.005330
after therapy was commenced have dis-:@0.084848:0.420063:0.475765:0.420063:0.475765:0.404307:0.084848:0.404307:0.013143:0.006042:0.006523:0.012508:0.005792:0.006933:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006947:0.015990:0.013143:0.007466:0.006947:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.012450:0.012508:0.013181:0.006929:0.011738:0.013143:0.010660:0.012508:0.006947:0.013181:0.003848:0.007466:0.006388
tinct prognostic relevance. Age (<1 year :@0.084848:0.436110:0.481105:0.436110:0.481105:0.420354:0.084848:0.420354:0.006523:0.003848:0.011738:0.012450:0.006523:0.007909:0.013123:0.005715:0.012604:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.007909:0.005713:0.012508:0.003848:0.012508:0.010660:0.013143:0.011738:0.012450:0.012508:0.005330:0.007909:0.014239:0.012950:0.012508:0.007909:0.007100:0.011661:0.010660:0.007909:0.010314:0.012508:0.013143:0.005792:0.005330
or  >9 years  in  children  and  <35 and  >60 :@0.084848:0.452157:0.481090:0.452157:0.481090:0.436401:0.084848:0.436401:0.012604:0.005792:0.005330:0.003194:0.011661:0.010660:0.008544:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.003204:0.003848:0.011738:0.005330:0.003202:0.012450:0.011738:0.003848:0.003848:0.013181:0.005719:0.012508:0.011738:0.005330:0.003198:0.013143:0.011738:0.013181:0.005330:0.003202:0.011661:0.010660:0.010660:0.008544:0.013143:0.011738:0.013181:0.005330:0.003202:0.011661:0.010660:0.010660:0.005330
in adults), leukocyte count (>30 x 10 /L for :@0.084848:0.468204:0.481103:0.468208:0.481103:0.452452:0.084848:0.452448:0.003848:0.011738:0.005907:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.007100:0.005330:0.005907:0.003848:0.012508:0.011699:0.009660:0.012604:0.012450:0.010314:0.006523:0.012508:0.005896:0.012450:0.012604:0.011699:0.011738:0.006523:0.005890:0.007100:0.011661:0.010660:0.010660:0.005907:0.009236:0.005907:0.010660:0.010660:0.006221:0.008409:0.008890:0.005907:0.006042:0.012604:0.005792:0.320660
9:@0.421911:0.462589:0.428126:0.462589:0.428126:0.453403:0.421911:0.453403:0.006215
precursor  B-ALL or  >100 x 10 /L in T-ALL) :@0.084844:0.484255:0.481109:0.484256:0.481109:0.468500:0.084844:0.468499:0.013123:0.005715:0.012508:0.012450:0.011699:0.005792:0.007466:0.012604:0.005792:0.005330:0.004503:0.011045:0.006388:0.014239:0.008890:0.008890:0.009852:0.012604:0.005792:0.005330:0.004507:0.011661:0.010660:0.010660:0.010660:0.009852:0.009236:0.009852:0.010660:0.010660:0.006218:0.008409:0.008890:0.009852:0.003848:0.011738:0.009852:0.008197:0.006388:0.014239:0.008890:0.008890:0.007100:0.297311
9:@0.363267:0.478637:0.369482:0.478637:0.369482:0.469451:0.363267:0.469451:0.006215
immunophenotype  (pro-B), CNS disease, :@0.084850:0.500303:0.481082:0.500303:0.481082:0.484547:0.084850:0.484547:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.013123:0.011738:0.012508:0.011738:0.012604:0.006523:0.010314:0.013123:0.012508:0.005330:0.003798:0.007100:0.013123:0.005719:0.012604:0.006388:0.011045:0.007100:0.005330:0.009140:0.015644:0.014239:0.009583:0.009140:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330
adverse karyotype and molecular abnor-:@0.084850:0.516350:0.475785:0.516350:0.475785:0.500594:0.084850:0.500594:0.013143:0.013181:0.010660:0.012508:0.005792:0.007466:0.012508:0.006725:0.009660:0.013143:0.005792:0.010314:0.012604:0.006523:0.010314:0.013123:0.012508:0.006735:0.013143:0.011738:0.013181:0.006723:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.006723:0.013143:0.013123:0.011738:0.012604:0.005792:0.006388
malities (BCR-ABL) are all unfavourable :@0.084850:0.532397:0.481090:0.532397:0.481090:0.516641:0.084850:0.516641:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.012585:0.007100:0.011045:0.015644:0.011680:0.006388:0.014239:0.011045:0.008890:0.007100:0.012585:0.013143:0.005715:0.012508:0.012585:0.013143:0.003848:0.003848:0.012585:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
factors and are considered in the choice :@0.084850:0.548444:0.481096:0.548444:0.481096:0.532688:0.084850:0.532688:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.006716:0.013143:0.011738:0.013181:0.006723:0.013143:0.005715:0.012508:0.006723:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.006721:0.003848:0.011738:0.006723:0.006523:0.011738:0.012508:0.006716:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.005330
of treatment modality (including referral :@0.084850:0.564491:0.481104:0.564491:0.481104:0.548735:0.084850:0.548735:0.012604:0.006042:0.009948:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.009948:0.018049:0.012604:0.013181:0.013143:0.003848:0.003848:0.006523:0.010314:0.009948:0.007100:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.009948:0.005713:0.012508:0.006042:0.012508:0.005792:0.005792:0.013143:0.003848:0.005330
for  allogeneic haemopoietic stem-cell :@0.084850:0.580538:0.481088:0.580538:0.481088:0.564782:0.084850:0.564782:0.006042:0.012604:0.005792:0.005330:0.011495:0.013143:0.003848:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.012450:0.016837:0.011738:0.013143:0.012508:0.018049:0.012604:0.013123:0.012604:0.003848:0.012508:0.006514:0.003848:0.012450:0.016837:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
transplantation).  Response  to  treatment :@0.084850:0.596585:0.481105:0.596585:0.481105:0.580829:0.084850:0.580829:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007100:0.005330:0.005330:0.006719:0.011680:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.006723:0.006523:0.012604:0.005330:0.006725:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
with undetectable disease by four weeks :@0.084850:0.612632:0.481073:0.612632:0.481073:0.596876:0.084850:0.596876:0.015990:0.003848:0.006523:0.011738:0.007043:0.011699:0.011738:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.013131:0.013123:0.003848:0.012508:0.007043:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007056:0.013123:0.010314:0.007043:0.006042:0.012604:0.011699:0.005792:0.007043:0.015990:0.012508:0.012508:0.009660:0.007466:0.005330
of induction therapy defines a biologically :@0.084850:0.628679:0.481075:0.628679:0.481075:0.612923:0.084850:0.612923:0.012604:0.006042:0.005026:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005024:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005026:0.013181:0.012508:0.004686:0.004686:0.011738:0.012508:0.007466:0.005026:0.013143:0.005032:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330
more favourable group.:@0.084850:0.644726:0.310052:0.644726:0.310052:0.628970:0.084850:0.628970:0.018049:0.012604:0.005707:0.012508:0.006177:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.006177:0.012950:0.005711:0.012604:0.011699:0.013123:0.005330
11-13:@0.310053:0.639116:0.338637:0.639116:0.338637:0.629931:0.310053:0.629931:0.006215:0.006215:0.003724:0.006215:0.006215
 With standard :@0.338646:0.644735:0.481077:0.644735:0.481077:0.628979:0.338646:0.628979:0.006177:0.018584:0.003848:0.006523:0.011738:0.006177:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005678:0.013181:0.005330
chemotherapy, there is an inverse relation-:@0.084839:0.660782:0.475751:0.660782:0.475751:0.645026:0.084839:0.645026:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003802:0.006523:0.011738:0.012508:0.005705:0.012508:0.003816:0.003848:0.007466:0.003829:0.013143:0.011738:0.003818:0.003848:0.011738:0.010660:0.012508:0.005792:0.007466:0.012508:0.003818:0.005713:0.012508:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388
ship between  the  number  of  risk factors :@0.084839:0.676829:0.481098:0.676829:0.481098:0.661073:0.084839:0.661073:0.007466:0.011738:0.003848:0.013123:0.009467:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.005330:0.004122:0.006523:0.011738:0.012508:0.005330:0.004122:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330:0.004120:0.012604:0.006042:0.005330:0.004127:0.005792:0.003848:0.007466:0.009660:0.009467:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330
and  survival,  with  five-year  survival  in  ex-:@0.084839:0.692876:0.475749:0.692876:0.475749:0.677120:0.084839:0.677120:0.013143:0.011738:0.013181:0.005330:0.003129:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.005330:0.003144:0.015990:0.003848:0.006523:0.011738:0.005330:0.003129:0.004686:0.004686:0.010660:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.005330:0.003127:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003142:0.003848:0.011738:0.005330:0.003129:0.012508:0.009236:0.006388
cess of 50% for none, to 20-40% with 1 or 2 :@0.084839:0.708923:0.481085:0.708923:0.481085:0.693167:0.084839:0.693167:0.012450:0.012508:0.007466:0.007466:0.005696:0.012604:0.006042:0.005686:0.010660:0.010660:0.014913:0.005696:0.006042:0.012604:0.005792:0.005680:0.011738:0.012604:0.011738:0.012508:0.005330:0.005678:0.006523:0.012604:0.005684:0.010660:0.010660:0.006388:0.010660:0.010676:0.014913:0.005696:0.015990:0.003848:0.006523:0.011738:0.005696:0.010660:0.005696:0.012604:0.005792:0.005682:0.010660:0.005330
and less than 10% in those with cumulative :@0.084839:0.724970:0.481090:0.724970:0.481090:0.709214:0.084839:0.709214:0.013143:0.011738:0.013181:0.004753:0.003848:0.012508:0.007466:0.007466:0.004753:0.006523:0.011738:0.013143:0.011738:0.004739:0.010660:0.010660:0.014913:0.004753:0.003848:0.011738:0.004753:0.006523:0.011738:0.012604:0.007466:0.012508:0.004739:0.015990:0.003848:0.006523:0.011738:0.004753:0.012450:0.011699:0.018049:0.011699:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330
incidence of 3 or 4 risk factors.:@0.084839:0.741017:0.372032:0.741017:0.372032:0.725261:0.084839:0.725261:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.006408:0.012604:0.006042:0.006408:0.010660:0.006408:0.012604:0.005792:0.006408:0.010660:0.006408:0.005792:0.003848:0.007466:0.009660:0.006408:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330
11,12:@0.372058:0.735404:0.400025:0.735404:0.400025:0.726218:0.372058:0.726218:0.006215:0.006215:0.003107:0.006215:0.006215
 Burkitt’s :@0.400032:0.741023:0.481081:0.741023:0.481081:0.725267:0.400032:0.725267:0.006408:0.011045:0.011699:0.005792:0.009660:0.003848:0.006523:0.006523:0.006754:0.007466:0.005330
leukaemia (L3 or mature B-cell; 5%) is asso-:@0.084841:0.757070:0.475764:0.757070:0.475764:0.741314:0.084841:0.741314:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.004772:0.007100:0.008890:0.010660:0.004772:0.012604:0.005792:0.004759:0.018049:0.013143:0.006523:0.011699:0.005709:0.012508:0.004759:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.004761:0.010660:0.014913:0.007100:0.004772:0.003848:0.007466:0.004772:0.013143:0.007466:0.007466:0.012604:0.006388
ciated with a variety of translocations that :@0.084841:0.773117:0.481100:0.773117:0.481100:0.757361:0.084841:0.757361:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.004965:0.015990:0.003848:0.006523:0.011738:0.004965:0.013143:0.004965:0.010660:0.013143:0.005792:0.003848:0.012508:0.006523:0.010314:0.004965:0.012604:0.006042:0.004965:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.012604:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.004965:0.006523:0.011738:0.013143:0.006523:0.005330
involve translocation of the :@0.084841:0.789164:0.349444:0.789164:0.349444:0.773408:0.084841:0.773408:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.007524:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.012604:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007524:0.012604:0.006042:0.007524:0.006523:0.011738:0.012508:0.005330
c-myc:@0.351637:0.789164:0.411289:0.789164:0.411289:0.773408:0.351637:0.773408:0.012450:0.006388:0.018049:0.010314:0.012450
 proto-:@0.411289:0.789164:0.475770:0.789164:0.475770:0.773408:0.411289:0.773408:0.007524:0.013123:0.005715:0.012604:0.006523:0.012604:0.006388
oncogene  to  the  immunoglobulin gene :@0.084841:0.805211:0.481100:0.805211:0.481100:0.789455:0.084841:0.789455:0.012604:0.011738:0.012450:0.012604:0.012950:0.012508:0.011738:0.012508:0.005330:0.005301:0.006523:0.012604:0.005330:0.005317:0.006523:0.011738:0.012508:0.005330:0.005315:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.012950:0.003848:0.012604:0.013123:0.011699:0.003848:0.003848:0.011738:0.010660:0.012950:0.012508:0.011738:0.012508:0.005330
locus t(2;8), t(8;12), and t(8;22).:@0.084841:0.821403:0.371726:0.821403:0.371726:0.805647:0.084841:0.805647:0.003848:0.012604:0.012450:0.011699:0.007466:0.005330:0.006523:0.007100:0.010660:0.005330:0.010660:0.007100:0.005330:0.005330:0.006523:0.007100:0.010660:0.005330:0.010660:0.010660:0.007100:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.006523:0.007100:0.010660:0.005330:0.010660:0.010660:0.007100:0.005330
11,13:@0.371746:0.815790:0.399714:0.815790:0.399714:0.806605:0.371746:0.806605:0.006215:0.006215:0.003107:0.006215:0.006215
THERAPY:@0.084848:0.854123:0.172936:0.854123:0.172936:0.836307:0.084848:0.836307:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
In children and adolescents, the treatment :@0.084848:0.871464:0.481099:0.871464:0.481099:0.855708:0.084848:0.855708:0.004349:0.011738:0.003798:0.012450:0.011738:0.003848:0.003848:0.013181:0.005721:0.012508:0.011738:0.003797:0.013143:0.011738:0.013181:0.003800:0.013143:0.013181:0.012604:0.003848:0.012508:0.007466:0.012450:0.012508:0.011738:0.006523:0.007466:0.005330:0.003797:0.006523:0.011738:0.012508:0.003793:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of ALL has been a significant therapeutic :@0.084848:0.887657:0.481101:0.887657:0.481101:0.871901:0.084848:0.871901:0.012604:0.006042:0.006991:0.014239:0.008890:0.008890:0.006987:0.011738:0.013143:0.007466:0.006998:0.013123:0.012508:0.012508:0.011738:0.006993:0.013143:0.006997:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.006997:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.005330
success, with over 80% of children surviving :@0.084848:0.903849:0.481076:0.903849:0.481076:0.888093:0.084848:0.888093:0.007466:0.011699:0.012450:0.012450:0.012508:0.007466:0.007466:0.005330:0.004310:0.015990:0.003848:0.006523:0.011738:0.004310:0.012604:0.010660:0.012508:0.005792:0.004301:0.010660:0.010660:0.014913:0.004310:0.012604:0.006042:0.004301:0.012450:0.011738:0.003848:0.003848:0.013181:0.005713:0.012508:0.011738:0.004301:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.003848:0.011738:0.012950:0.005330
in  the  long-term.  Treatment  approaches :@0.084848:0.920042:0.481092:0.920042:0.481092:0.904286:0.084848:0.904286:0.003848:0.011738:0.005330:0.004416:0.006523:0.011738:0.012508:0.005330:0.004414:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006310:0.018049:0.005330:0.005330:0.004412:0.007620:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004407:0.013143:0.013123:0.013123:0.005721:0.012604:0.013143:0.012450:0.011738:0.012508:0.007466:0.005330
for adolescents and young adults with ALL :@0.084848:0.936234:0.481090:0.936234:0.481090:0.920478:0.084848:0.920478:0.006042:0.012604:0.005792:0.004943:0.013143:0.013181:0.012604:0.003848:0.012508:0.007466:0.012450:0.012508:0.011738:0.006523:0.007466:0.004949:0.013143:0.011738:0.013181:0.004951:0.010314:0.012604:0.011699:0.011738:0.012950:0.004943:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.004955:0.015990:0.003848:0.006523:0.011738:0.004951:0.014239:0.008890:0.008890:0.005330
have also evolved considerably in the past :@0.524249:0.362737:0.920479:0.362737:0.920479:0.346981:0.524249:0.346981:0.011738:0.013143:0.010660:0.012508:0.003868:0.013143:0.003848:0.007466:0.012604:0.003868:0.012508:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.003868:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.013123:0.003848:0.010314:0.003868:0.003848:0.011738:0.003868:0.006523:0.011738:0.012508:0.003858:0.013123:0.013143:0.007466:0.006523:0.005330
five  to  seven  years.:@0.524249:0.379127:0.711250:0.379127:0.711250:0.363372:0.524249:0.363372:0.004686:0.004686:0.010660:0.012508:0.005330:0.003306:0.006523:0.012604:0.005330:0.003300:0.007466:0.012508:0.010660:0.012508:0.011738:0.005330:0.003308:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330
12,13:@0.711243:0.373507:0.739210:0.373507:0.739210:0.364322:0.711243:0.364322:0.006215:0.006215:0.003107:0.006215:0.006215
 However, in older :@0.739218:0.379126:0.920498:0.379126:0.920498:0.363370:0.739218:0.363370:0.008640:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003770:0.005330:0.008640:0.003848:0.011738:0.008640:0.012604:0.003848:0.013181:0.012508:0.005792:0.005330
adults, therapy of this malignancy remains :@0.524241:0.395517:0.920485:0.395517:0.920485:0.379761:0.524241:0.379761:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.005330:0.004936:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004934:0.012604:0.006042:0.004928:0.006523:0.011738:0.003848:0.007466:0.004934:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.004945:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.005330
a major challenge. Similar to the treatment :@0.524241:0.411908:0.920491:0.411908:0.920491:0.396152:0.524241:0.396152:0.013143:0.003829:0.018049:0.013143:0.003906:0.012604:0.005792:0.003829:0.012450:0.011738:0.013143:0.003848:0.003848:0.012508:0.011738:0.012950:0.012508:0.005330:0.003829:0.009583:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.003843:0.006523:0.012604:0.003829:0.006523:0.011738:0.012508:0.003829:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of AML, optimal management of patients :@0.524241:0.428299:0.920496:0.428299:0.920496:0.412543:0.524241:0.412543:0.012604:0.006042:0.006223:0.014239:0.017684:0.008890:0.005330:0.006235:0.012604:0.013123:0.006523:0.003848:0.018049:0.013143:0.003848:0.006235:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.006217:0.012604:0.006042:0.006221:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with ALL requires careful attention to sup-:@0.524241:0.444690:0.915162:0.444690:0.915162:0.428934:0.524241:0.428934:0.015990:0.003848:0.006523:0.011738:0.006646:0.014239:0.008890:0.008880:0.006646:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.007466:0.006658:0.012450:0.013143:0.005713:0.012508:0.006042:0.011699:0.003848:0.006646:0.013143:0.006523:0.006523:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.006641:0.006523:0.012604:0.006639:0.007466:0.011699:0.013123:0.006388
portive care. Metabolic derangements :@0.524241:0.461081:0.920498:0.461081:0.920498:0.445325:0.524241:0.445325:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.014297:0.012450:0.013143:0.005713:0.012508:0.005330:0.014297:0.017684:0.012508:0.006523:0.013143:0.013123:0.012604:0.003848:0.003848:0.012450:0.014297:0.013181:0.012508:0.005792:0.013143:0.011738:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330
are frequently encountered, even before :@0.524241:0.477472:0.920506:0.477472:0.920506:0.461716:0.524241:0.461716:0.013143:0.005715:0.012508:0.006793:0.006042:0.005711:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.006793:0.012508:0.011738:0.012450:0.012604:0.011699:0.011738:0.006523:0.012508:0.005694:0.012508:0.013181:0.005330:0.006793:0.012508:0.010660:0.012508:0.011738:0.006793:0.013123:0.012508:0.006042:0.012604:0.005707:0.012508:0.005330
chemotherapy  is initiated, especially  in :@0.524241:0.493863:0.920469:0.493863:0.920469:0.478107:0.524241:0.478107:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.007147:0.003848:0.007466:0.012488:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.012488:0.012508:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.003848:0.010314:0.005330:0.007177:0.003848:0.011738:0.005330
patients with a high leukaemic cell burden :@0.524241:0.510254:0.920460:0.510254:0.920460:0.494498:0.524241:0.494498:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004368:0.015990:0.003848:0.006523:0.011738:0.004368:0.013143:0.004368:0.011738:0.003848:0.012950:0.011738:0.004368:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.012450:0.004368:0.012450:0.012508:0.003848:0.003848:0.004368:0.013123:0.011699:0.005675:0.013181:0.012508:0.011738:0.005330
and those with T-cell or mature B-cell ALL. :@0.524241:0.526645:0.920493:0.526645:0.920493:0.510889:0.524241:0.510889:0.013143:0.011738:0.013181:0.006177:0.006523:0.011738:0.012604:0.007466:0.012508:0.006167:0.015990:0.003848:0.006523:0.011738:0.006177:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.006177:0.012604:0.005792:0.006165:0.018049:0.013143:0.006523:0.011699:0.005709:0.012508:0.006177:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.006177:0.014239:0.008890:0.008890:0.005330:0.005330
Patients receiving induction therapy de-:@0.524241:0.543036:0.915168:0.543036:0.915168:0.527280:0.524241:0.527280:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009679:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.009679:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.009679:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.009679:0.013181:0.012508:0.006388
velop severe pancytopaenia and require :@0.524241:0.559426:0.920498:0.559426:0.920498:0.543671:0.524241:0.543671:0.010660:0.012508:0.003848:0.012604:0.013123:0.006562:0.007466:0.012508:0.010660:0.012508:0.005715:0.012508:0.006562:0.013123:0.013143:0.011738:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.006562:0.013143:0.011738:0.013181:0.006562:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.005330
similar supportive care to those with AML. :@0.524241:0.575817:0.920504:0.575817:0.920504:0.560061:0.524241:0.560061:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.006600:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.006600:0.012450:0.013143:0.005713:0.012508:0.006591:0.006523:0.012604:0.006587:0.006523:0.011738:0.012604:0.007466:0.012508:0.006591:0.015990:0.003848:0.006523:0.011738:0.006600:0.014239:0.017684:0.008890:0.005330:0.005330
Infections need to be treated aggressively :@0.524241:0.592208:0.920469:0.592208:0.920469:0.576452:0.524241:0.576452:0.004349:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.004695:0.011738:0.012508:0.012508:0.013181:0.004695:0.006523:0.012604:0.004695:0.013123:0.012508:0.004695:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.004695:0.013143:0.012950:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330
based on empiric and culture-directed :@0.524241:0.608599:0.920477:0.608599:0.920477:0.592843:0.524241:0.592843:0.013123:0.013143:0.007466:0.012508:0.013181:0.012180:0.012604:0.011738:0.012180:0.012508:0.018049:0.013123:0.003848:0.005792:0.003848:0.012450:0.012180:0.013143:0.011738:0.013181:0.012180:0.012450:0.011699:0.003848:0.006523:0.011699:0.005711:0.012508:0.006388:0.013181:0.003848:0.005715:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330
antibiotic combinations.:@0.524241:0.624990:0.749685:0.624990:0.749685:0.609234:0.524241:0.609234:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.012604:0.006523:0.003848:0.012450:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
The  specific  treatment  of  ALL  also  in-:@0.542425:0.641381:0.915151:0.641381:0.915151:0.625625:0.542425:0.625625:0.008197:0.011738:0.012508:0.005330:0.005688:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330:0.005702:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005688:0.012604:0.006042:0.005330:0.005692:0.014239:0.008890:0.008890:0.005330:0.005688:0.013143:0.003848:0.007466:0.012604:0.005330:0.005703:0.003848:0.011738:0.006388
cludes a remission-induction  phase and :@0.524241:0.657772:0.920487:0.657772:0.920487:0.642016:0.524241:0.642016:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.010833:0.013143:0.010833:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005492:0.013123:0.011738:0.013143:0.007466:0.012508:0.010833:0.013143:0.011738:0.013181:0.005330
post-remission maintenance therapy. Most :@0.524241:0.674163:0.920479:0.674163:0.920479:0.658407:0.524241:0.658407:0.013123:0.012604:0.007466:0.006523:0.006388:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.003810:0.018049:0.013143:0.003848:0.011738:0.006523:0.012508:0.011738:0.013143:0.011738:0.012450:0.012508:0.003810:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003810:0.017684:0.012604:0.007466:0.006523:0.005330
induction regimens include combination :@0.524241:0.690554:0.920479:0.690554:0.920479:0.674798:0.524241:0.674798:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.009852:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.009852:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.009852:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
chemotherapy  consisting of vincristine, :@0.524241:0.706945:0.920498:0.706945:0.920498:0.691189:0.524241:0.691189:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.009792:0.012450:0.012604:0.011738:0.007466:0.003848:0.007466:0.006523:0.003848:0.011738:0.012950:0.015144:0.012604:0.006042:0.015144:0.010660:0.003848:0.011738:0.012450:0.005792:0.003848:0.007466:0.006523:0.003848:0.011738:0.012508:0.005330:0.005330
prednisone, anthracycline, L-asparginase :@0.524241:0.723336:0.920485:0.723336:0.920485:0.707580:0.524241:0.707580:0.013123:0.005715:0.012508:0.013181:0.011738:0.003848:0.007466:0.012604:0.011738:0.012508:0.005330:0.008486:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.008486:0.008890:0.006388:0.013143:0.007466:0.013123:0.013143:0.005815:0.012950:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
and alkylators such  as cyclophospha-:@0.524241:0.739727:0.915160:0.739727:0.915160:0.723971:0.524241:0.723971:0.013143:0.011738:0.013181:0.015394:0.013143:0.003848:0.009660:0.010314:0.003848:0.013143:0.006523:0.012604:0.005792:0.007466:0.015394:0.007466:0.011699:0.012450:0.011738:0.005330:0.010054:0.013143:0.007466:0.015394:0.012450:0.010314:0.012450:0.003848:0.012604:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006388
mide. To avert meningeal leukaemia dur-:@0.524241:0.756118:0.915162:0.756118:0.915162:0.740362:0.524241:0.740362:0.018049:0.003848:0.013181:0.012508:0.005330:0.006744:0.007252:0.012604:0.006744:0.013143:0.010660:0.012508:0.005792:0.006523:0.006743:0.018049:0.012508:0.011738:0.003848:0.011738:0.012950:0.012508:0.013143:0.003848:0.006741:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.006754:0.013181:0.011699:0.005792:0.006388
ing  induction,  all patients should receive :@0.524241:0.772509:0.920491:0.772509:0.920491:0.756753:0.524241:0.756753:0.003848:0.011738:0.012950:0.005330:0.003262:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.003254:0.013143:0.003848:0.003848:0.008601:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008601:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.008601:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.005330
CNS  prophylaxis with  intrathecal chemo-:@0.524241:0.788900:0.915151:0.788900:0.915151:0.773144:0.524241:0.773144:0.015644:0.014239:0.009583:0.005330:0.003215:0.013123:0.005715:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.008563:0.015990:0.003848:0.006523:0.011738:0.005330:0.003219:0.003848:0.011738:0.006523:0.005792:0.013143:0.006523:0.011738:0.012498:0.012450:0.013143:0.003848:0.008563:0.012450:0.011738:0.012508:0.018049:0.012586:0.006388
therapy  (steroids, methotrexate  and/or :@0.524241:0.805290:0.920496:0.805290:0.920496:0.789535:0.524241:0.789535:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.009204:0.007100:0.007466:0.006523:0.012508:0.005715:0.012604:0.003848:0.013181:0.007466:0.005330:0.014547:0.018049:0.012508:0.006523:0.011738:0.012604:0.006523:0.005698:0.012508:0.009236:0.013143:0.006523:0.012508:0.005330:0.009206:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.005330
cytarabine).   Clinical studies  have  dem-:@0.524241:0.821681:0.915142:0.821543:0.915142:0.805787:0.524241:0.805925:0.012450:0.010314:0.006523:0.013143:0.005792:0.013143:0.013123:0.003848:0.011738:0.012508:0.007100:0.005330:0.012436:0.005330:0.003221:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.008563:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.003223:0.011738:0.013143:0.010660:0.012508:0.005330:0.003221:0.013181:0.012508:0.018049:-0.626263
14:@0.639255:0.815924:0.651685:0.815924:0.651685:0.806738:0.639255:0.806738:0.006215:0.006215
onstrated that post-remission consolida-:@0.524246:0.837934:0.915152:0.837934:0.915152:0.822178:0.524246:0.822178:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.012296:0.006523:0.011738:0.013143:0.006523:0.012296:0.013123:0.012604:0.007466:0.006523:0.006388:0.005711:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.012296:0.012450:0.012604:0.011738:0.007466:0.012604:0.003848:0.003848:0.013181:0.013143:0.006388
tion with high doses of methotrexate (with :@0.524246:0.854325:0.920496:0.854325:0.920496:0.838569:0.524246:0.838569:0.006523:0.003848:0.012604:0.011738:0.005528:0.015990:0.003848:0.006523:0.011738:0.005542:0.011738:0.003848:0.012950:0.011738:0.005530:0.013181:0.012604:0.007466:0.012508:0.007466:0.005542:0.012604:0.006042:0.005528:0.018049:0.012508:0.006523:0.011738:0.012592:0.006523:0.005711:0.012508:0.009236:0.013143:0.006523:0.012508:0.005528:0.007100:0.015990:0.003848:0.006523:0.011738:0.005330
folinic acid rescue),  cytarabine with  the :@0.524246:0.870716:0.920503:0.870716:0.920503:0.854960:0.524246:0.854960:0.006042:0.012604:0.003848:0.003848:0.011738:0.003848:0.012450:0.009544:0.013143:0.012450:0.003848:0.013181:0.009544:0.005713:0.012508:0.007466:0.012450:0.011699:0.012508:0.007100:0.005330:0.005330:0.004204:0.012450:0.010314:0.006523:0.013143:0.005792:0.013143:0.013123:0.003848:0.011738:0.012508:0.009544:0.015990:0.003848:0.006523:0.011738:0.005330:0.004204:0.006523:0.011738:0.012508:0.005330
addition of vinca alkaloids or L-aspargin-:@0.524246:0.887107:0.915156:0.887107:0.915156:0.871351:0.524246:0.871351:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.008063:0.012604:0.006042:0.008063:0.010660:0.003848:0.011738:0.012450:0.013143:0.008063:0.013143:0.003848:0.009660:0.013143:0.003848:0.012604:0.003848:0.013181:0.007466:0.008078:0.012604:0.005792:0.008063:0.008890:0.006388:0.013143:0.007466:0.013123:0.013143:0.005815:0.012950:0.003848:0.011738:0.006388
ase over a period of six months increases :@0.524246:0.903498:0.920501:0.903498:0.920501:0.887742:0.524246:0.887742:0.013143:0.007466:0.012508:0.006850:0.012604:0.010660:0.012508:0.005792:0.006835:0.013143:0.006850:0.013123:0.012508:0.005792:0.003848:0.012604:0.013181:0.006841:0.012604:0.006042:0.006835:0.007466:0.003848:0.009236:0.006850:0.018049:0.012604:0.011738:0.006514:0.011738:0.007466:0.006841:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330
overall survival due to a reduction of dis-:@0.524246:0.919889:0.915158:0.919889:0.915158:0.904133:0.524246:0.904133:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.007428:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003864:0.007418:0.013181:0.011699:0.012508:0.007416:0.006523:0.012604:0.007412:0.013143:0.007428:0.005711:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.007410:0.012604:0.006042:0.007414:0.013181:0.003848:0.007466:0.006388
ease recurrence.:@0.524246:0.936280:0.683599:0.936280:0.683599:0.920524:0.524246:0.920524:0.012508:0.013143:0.007466:0.012508:0.005330:0.005711:0.012508:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.012450:0.012508:0.005330
Figure 3. Cytological preparation (May-:@0.524246:0.096598:0.857175:0.096598:0.857175:0.080207:0.524246:0.080207:0.009756:0.005272:0.011257:0.011218:0.007158:0.010160:0.003887:0.010680:0.005003:0.003887:0.010812:0.010064:0.006966:0.011103:0.005292:0.011161:0.011257:0.005272:0.008755:0.010160:0.005292:0.003887:0.011507:0.007156:0.010160:0.011507:0.010160:0.007102:0.010006:0.007062:0.005272:0.011103:0.011276:0.003887:0.006042:0.016335:0.009929:0.009929:0.006196
Grünwald-Giemsa) of lymphoblastic :@0.524246:0.112036:0.835779:0.112036:0.835779:0.095646:0.524246:0.095646:0.013181:0.007254:0.011218:0.010910:0.014470:0.010160:0.005292:0.011468:0.006427:0.013179:0.005272:0.010160:0.016548:0.008351:0.010160:0.006042:0.003887:0.011103:0.006562:0.003887:0.005292:0.010064:0.016548:0.011507:0.011276:0.011103:0.011507:0.005292:0.010160:0.008351:0.007062:0.005272:0.008678:0.003887
leukaemia cells:@0.524246:0.127475:0.655189:0.127475:0.655189:0.111084:0.524246:0.111084:0.005292:0.010160:0.011218:0.010526:0.010160:0.010160:0.016548:0.005272:0.010160:0.003887:0.008465:0.010160:0.005292:0.005292:0.008351